Human leukemic cells, maintained in tissue culture, responded differentially following exposure to the phorbol ester tumor promoter 12-0-tetradecanoylphorbol-13-acetate (TPA). Short-term (0-2 h) TPA treatment of hairy cell leukemic cells (of presumed B-lymphocytic origin) resulted in the attachment of 5-100% of cells (depending on % leukemic mononuclear cells) to the culture dish and extension of long processes. Similar changes were also observed with cells from acute myelogenous, acute prolymphocytic and some acute monomyelocytic leukemic patients. Related non-promoters such as phorbol and 4-alpha-phorbol-12, 13-didecanoate, had no effect. In contrast, both chronic and acute lymphocytic, chronic myelogenous and acute promyelocytic leukemic cells showed no response to TPA over this short time period. Neither the adherence nor morphological changes were blocked by inhibitors of protein synthesis (cycloheximide) or glycosylation (tunicamycin), but the process formation was sensitive to inhibitors of microtubule formation such as colchicine. The effect was not reversible by TPA removal, and exposure to TPA for only 5 min resulted in a complete adherence and morphological induction within 60 min.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0145-2126(85)90092-xDOI Listing

Publication Analysis

Top Keywords

leukemic cells
16
hairy cell
8
human leukemic
8
phorbol ester
8
ester tumor
8
myelogenous acute
8
adherence morphological
8
cells
7
leukemic
6
tpa
5

Similar Publications

Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.

Heliyon

January 2025

Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Acute myeloid leukemia is the expansion of leukemic stem cells which might originate from a stem cell or a progenitor which has acquired self-renewal capacity. An aggregation of leukemic blasts in bone marrow, peripheral blood, and extramedullary tissue will result in acute myeloid leukemia. The main difficulty in treating acute myeloid leukemia is multidrug resistance, leading to treatment failure.

View Article and Find Full Text PDF

MircoRNAs predict and modulate responses to chemotherapy in leukemic patients.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Oral Biology Department, Faculty of Dentistry, Galala Plateau, Galala University, 15888), Attaka, Suez Governorate, Egypt.

Leukemia covers a broad category of cancer malignancies that specifically affect bone marrow and blood cells. While different kinds of leukemia have been identified, effective treatments are still lacking for most forms, and even those treatments considered effective can lead to relapses. MicroRNAs, or miRNAs, are short endogenous non-coding single-stranded RNAs that help control the epigenetics of gene expression.

View Article and Find Full Text PDF

Background: Acute myeloid leukemia (AML) is a hematologic malignancy. It is the most common form of acute leukemia among adults. Recent treatment advances have drastically improved outcomes for these diseases, but the overall survival (OS) is still exceptionally low due to the infiltration of leukemic cells in the central nervous system (CNS).

View Article and Find Full Text PDF

CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia.

Nat Commun

January 2025

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.

Acute myeloid leukemia (AML) with retinoic acid receptor gamma (RARG) fusions, which exhibits clinical features resembling acute promyelocytic leukemia (APL), has been identified as a new subtype with poor clinical outcomes. The underlying mechanism of RARG-fusion leukemia remains poorly understood, and needs to be explored urgently to instruct developing effective therapeutic strategies. Here, using the most prevalent RARG fusion, CPSF6-RARG (CR), as a representative, we reveal that the CR fusion, enhances the expansion of myeloid progenitors, impairs their maturation and synergizes with RAS mutations to drive more aggressive myeloid malignancies.

View Article and Find Full Text PDF

Inversion of chromosome 16 [inv(16)] is one of the most common chromosomal rearrangements in Acute Myeloid Leukemia (AML) and generates the fusion gene , which initiates leukemogenesis. Patients with inv(16) at diagnosis invariably have the rearrangement at relapse, leading to the assumption that is required after leukemic transformation. However, this has yet to be shown experimentally.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!